Risk factor
Critical default risk
Profitability factor
Greatly undervalued vs peers
About
Presently, Immage Biotherapeutics Corp. lacks substantial business operations. Historically, its endeavors centered on the creation of cutting-edge immunotherapy biologics designed to combat diverse cancer types across the United States. Established in 2012, the entity was initially known as Epicure Charcoal, Inc., rebranding to Immage Biotherapeutics Corp. in June 2015. Its corporate headquarters are situated in Bethesda, Maryland, and it operates as a subsidiary of Coventry International Limited.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is undervalued on EV/EBITDA.